ArticleCureus2024
Prognostic Factors of Hodgkin's Disease Recurrence: An Experience From a Tertiary Academic Center in Iran.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Despite the favorable prognosis of Hodgkin's disease (HD), some patients experience disease recurrence. Therefore, determining recurrence prognostic factors is very crucial to identify patients at risk of early relapse, maintain remission, and improve outcomes. Materials and methods This retrospective cohort study enrolled HD patients at the National Research Institute of Tuberculosis and Lung Disease (NRITLD), Masih Daneshvari Hospital, between January 1, 2002, and June 30, 2018. Demographic characteristics and clinical outcomes, including response to treatment, disease progression, and survival data, were considered. Results Two hundred fifty patients were enrolled. The mean age at diagnosis was 30.03 years. The female-to-male ratio was 1.06:1. Eighty-five (34%) disease recurrences occurred within the study period, most occurring before three years of initial diagnosis. The mean of progression-free survival (PFS) was 18.4 months. In both univariate and multivariate analyses, the advanced stage (stage IV) was significantly associated with shorter PFS (P=0.0001 and P=0.004, respectively). Also, shorter PFS was observed in the presence of bulky tumors (P=0.037/univariate analysis) and high-risk International Prognostic Score (IPS) (P=0.030/multivariate analysis). Conclusion Our findings in the Iranian HD patient cohort revealed that the risk of disease recurrence is higher in the presence of some clinical characteristics such as bulky disease, higher IPS, and advanced stage which needs special attention. Close follow-up, especially within three years after initial diagnosis, has a great importance to detect early relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.